Study #2019-0191
Hydroxychloroquine and binimetinib in KRASmt metastatic Pancreatic cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Binimetinib, Hydroxychloroquine
Description
This phase I trial studies the best dose of hydroxychloroquine when given together with binimetinib in treating patients with KRAS gene mutated pancreatic cancer that has spread to other places in the body (metastatic). Binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hydroxychloroquine may prevent autophagy, a normal process in which a cell destroys proteins and other substances which may lead to cell death. Autophagy may prevent normal cells from developing into tumor cells, but it may also protect tumor cells by destroying anticancer drugs or substances taken up by them. Giving hydroxychloroquine together with binimetinib may work better in treating patients with pancreatic cancer compared to binimetinib alone.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC V8
Study phase:
Phase I
Physician name:
Shubham Pant
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-833-676-1615
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.